Journal of Clinical Oncology
Articles in this Issue
Clinical outcomes of Kaposi's sarcoma in a cohort of HIV-negative men who have sex with men: An observational study (2000–2024).
e23538 Background: Kaposi's sarcoma (KS) is a multifocal vascular neoplasm associated with human herpesvirus-8 (HHV-8) infection. Historically, four main...
Frailty index as a predictor of postoperative outcomes in oral carcinoma patients undergoing surgery: A tertiary care center study.
e18049 Background: Frailty is increasingly recognized as a key predictor of adverse outcomes in surgical patients, particularly in those undergoing comple...
Neoadjuvant immunotherapy for patients with resectable stage III/IV cutaneous melanoma: A Swedish retrospective real-world study (NEO-MEL).
e21563 Background: Recent clinical trials have demonstrated that neoadjuvant administration of PD-1 +/- CTLA-4 inhibitor is superior to adjuvant PD-1 inhi...
Influence of salmonella-IL2 in combination with FOLFIRINOX on overall and progression-free survival in stage IV metastatic pancreatic cancer.
2571 Background: Salmonella-IL2 is an attenuated Salmonella Typhimurium strain carrying the human gene for IL-2. When orally administered, the bacterium c...
Osimertinib plus anlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer with concurrent gene alterations: A single-arm, prospective, multicenter phase II study.
8627 Background: The standard first-line treatment for advanced EGFR-mutated non-small cell lung cancer (NSCLC) is EGFR tyrosine kinase inhibitors (EGFR-T...
Randomized phase I trial of adjuvant personalized cancer vaccine TG4050 in resected locally advanced (LA) head and neck squamous cell carcinoma (HNSCC) patients (pts).
6016 Background: Approximately one third of pts with resected LA HNSCC recur. T-cells targeting tumor specific mutations drive anti-tumor immune responses...
Association between oral contraceptive use and pancreatic cancer risk: An updated systematic review and meta-analysis.
e16399 Background: Pancreatic cancer (PC) is the most aggressive malignancy of the gastrointestinal tract, with limited modifiable risk factors identified...
Incidence and outcomes of immune checkpoint inhibitor (ICI) rechallenge after ICI pneumonitis: A single-center retrospective study.
2659 Background: Limited evidence is available on the safety and efficacy of immune checkpoint inhibitor (ICI) rechallenge following an immune-related adv...
Clinical outcomes for Medicare recipients with early-onset breast cancer: An analysis of the National Inpatient Sample.
e23355 Background: Despite recent global decreases in overall cancer incidence, the incidence of early-onset breast cancer (EOBC) is steadily increasing g...
Increasing lung cancer screening education among minoritized populations.
e13740 Background: In 2024, lung cancer remained the leading cause of cancer-related death in the United States. Low dose computed tomography (LDCT) has b...
Cadonilimab plus platinum-based chemotherapy ± bevacizumab for persistent, recurrent, or metastatic cervical cancer: Subgroup analyses of COMPASSION-16.
5509 Background: The phase 3 COMPASSION-16 trial demonstrated statistically significant progression-free survival (PFS) and overall survival (OS) benefits...
Regional and demographic trends in mortality from breast cancer and cerebrovascular diseases in United States from 1999-2019: A retrospective analysis.
e13776 Background: Breast cancer and cerebrovascular diseases significantly contribute to mortality in the United States, with disparities observed across...
Role of Lu177 FAPI-09 therapy in combination with chemotherapy or immunotherapy for chemo-resistant progressive cancers: Early clinical experience.
3094 Background: Chemo resistant progressive tumours represent a major challenge in oncology. These tumours often adapt and develop resistance mechanisms...
Phase I/Ib study of inavolisib (INAVO) alone and in combination with endocrine therapy ± palbociclib (PALBO) in patients (pts) with <i>PIK3CA</i> -mutated, hormone receptor–positive, HER2-negative locally advanced/metastatic breast cancer (HR+, HER2– LA/mBC): Analysis of hyperglycemia (HG) in prediabetic/obese pts.
1004 Background: INAVO, a highly potent and selective PI3Kα inhibitor that also promotes degradation of mutated p110α, is approved by the FDA in combinati...
Real-world data on the management of potentially resectable stage IB-IIIA non-small cell lung cancer (NSCLC) in the United Kingdom (UK) in 2023: Early adoption of immune checkpoint inhibitors (ICIs).
e20618 Background: Although early-stage resectable stage IB-IIIA NSCLC has a better prognosis, it is associated with high recurrence rates within the firs...
Microbiota proteomics profiles in muscle-invasive bladder carcinoma related to response to neoadjuvant chemotherapy.
4589 Background: Muscle-invasive bladder carcinoma (MIBC) poses significant challenges due to high recurrence and mortality rates, coupled with the toxici...
Early supportive and palliative care referral at a comprehensive cancer center: A seven year study.
12088 Background: Despite ASCO supporting the benefits of early supportive/palliative care (SPC) integration, many patients with advanced cancer were refe...
Endometrial cancer mortality in the U.S.: Insights into inequities across demographics and regions.
e22577 Background: Endometrial cancer, the most prevalent gynecological malignancy, presents a significant public health concern, with disparities in inci...
Prognostic relevance of Aurora kinase A ( <i>AURKA</i> ) expression in prostate cancer (PCa).
5061 Background: Amplification and overexpression of the AURKA gene characterize aggressive variants of prostate cancer, such as c...
The role of gut microbiome composition in the IBD-CRC pathway: A retrospective study of 428 patients.
3571 Background: The progression from inflammatory bowel disease (IBD) to colorectal cancer (CRC) is a significant clinical challenge, driven partly by in...
Characteristics of patients with lung cancer at a large safety net health system: Implications for health equity.
e13840 Background: Lung cancer remains the leading cause of cancer deaths in both men and women in the United States. Lack of access to health care and sc...
Role of low dose capecitabine and erlotinib in treatment of recurrent or metastatic head and neck cancer.
e18003 Background: Head and neck squamous cell carcinoma (HNSCC) is one of the most common cancers in Pakistan. Its incidence is rising continuously due t...
Role of ADAR1 loss in lung cancer on anti-tumor immunity and tumor cell growth via the RIG-I/MDA5-MAVS pathway.
e20599 Background: Aberrant accumulation of dsDNA in tumour cells activates the cGAS-STING pathway, playing a crucial role in anti-tumour immunity. Howeve...
Relationship between aperiodic dynamics and transcriptomic alterations and a neural signature of glioma-induced excitation-inhibition dysregulation.
2062 Background: Diffuse gliomas disrupt neuronal dynamics, leading to excitation-inhibition (E/I) imbalance and associated functional impairments. The ap...
Efficacy and safety of MHB088C, a novel B7-H3-targeted ADC, in patients with relapsed extensive-stage small cell lung cancer (ES-SCLC): Subgroup analysis from a phase 1/2 multicenter study.
8510 Background: MHB088C is a novel B7-H3-targeted antibody-drug conjugate (ADC) containing the potent SuperTopoi payload that is 5 to 10 times more poten...